MicroRNA-221 silencing attenuates the degenerated phenotype of intervertebral disc cells. by Penolazzi, L et al.




Defective homeostatic mechanisms and accumulation of 
molecular damages in spine injuries and spine disorders 
must be elucidated. A particularly complicated scenario 
is represented by intervertebral disc degeneration 
(IDD), a multifactorial disease without effective preven-
tive and therapeutic approaches [1,2]. The complex 
cellular fibrocartilaginous structure and mechanical 
environment of the intervertebral disc (IVD) make it 
difficult to obtain unequivocal data and set up 
appropriate/informative experimental models [3]. 
Consequently,  many studies which are mainly aimed  at  
 
developing novel therapeutics based on the local 
injection of cells or biological agents for IVD repair 
produce conflicting data. 
 
The IVD is composed of a hydrophilic proteoglycan-
rich gelatinous core, the nucleus pulposus (NP), which 
is surrounded by a lamellated collagenous ring, the 
annulus fibrosus (AF), and cartilaginous and bony end-
plates that separate the disc from the vertebrae [3]. 
Degeneration begins when anabolic and catabolic 
activities of IVD mature and progenitor cells become 
unbalanced due to negative stimuli including genetic 
risk, mechanical trauma, injuries, smoking, obesity and 
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The  aim  of  this  study  was  to  investigate  the  role  of  an  antichondrogenic  factor,  MIR221  (miR‐221),  in
intervertebral disc degeneration  (IDD),  and provide basic  information  for  the development  of  a  therapeutic
strategy for the disc repair based on specific nucleic acid based drugs, such as miR‐221 silencing. We established
a relatively quick protocol to minimize artifacts from extended in vitro culture, without selecting the different
types of cells  from  intervertebral disc  (IVD) or completely disrupting extracellular matrix  (ECM), but by using
the  whole  cell  population  with  a  part  of  resident  ECM.  During  the  de‐differentiation  process  miR‐221
expression significantly increased. We demonstrated the effectiveness of miR‐221 silencing in driving the cells
towards chondrogenic lineage. AntagomiR‐221 treated cells showed in fact a significant increase of expression
of  typical  chondrogenic  markers  including  COL2A1,  ACAN  and  SOX9,  whose  loss  is  associated  with  IDD.
Moreover,  antagomiR‐221  treatment  restored  FOXO3  expression  and  increased  TRPS1  expression  levels
attenuating  the  severity  grade  of degeneration,  and demonstrating  in  a  context of  tissue degeneration  and
inflammation not investigated before, that FOXO3 is target of miR‐221. Data of present study are promising in
the definition of new molecules useful as potential intradiscal injectable biological agents.  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ageing [4,5]. This causes a change in tissue architecture, 
cell density and extracellular matrix (ECM) composition; 
the nucleus infiltrates the annulus and the cellular 
components mix together. Consequently, a variety of 
cells coexist in the degenerated micro-environment such 
as neurons, chondrocytes, and osteoblasts which come 
from both surrounding spinal tissue or differentiation of 
progenitor cells resident in the disc [1,2,5]. Therefore, 
when investigating IDD local microenvironment it must 
take into account the difficulties of both acquiring a 
uniform IVD tissue or obtaining homogeneous cell sub-
populations. However, in a scenario like this it is not 
always necessary/convenient to sort single cell popula-
tions, but rather to try to preserve in vitro the properties 
of the endogenous microenvironment to obtain 
informative results. Therefore, the idea of not selecting 
the different types of cells, but of using the whole cell 
population with a part of resident ECM, is becoming 
increasingly convincing.  Following this hypothesis, we 
are interested in understanding the endogenous properties 
of IVD cells and investigating the effectiveness of 
nucleic acid based drug treatments in the reverting 
degenerated phenotype. 
 
In recent years, an increasing number of reports have 
described microRNAs (miRNAs) as key players in IDD 
[6-9]. Some miRNAs have been associated with 
apoptosis, ECM degradation, cell proliferation and 
senescence, oxidative stress and inflammation that are 
well known in promoting and maintaining IDD. There-
fore, in addition to diagnostic and prognostic markers, 
miRNAs have also been proposed as potential thera-
peutic targets in order to promote disc repair [5]. 
Previously, we showed that antimiR-mediated silencing 
of MIR221 (miR-221) in human mesenchymal stem 
cells (hMSCs) functions as a potent pro-chondrogenic 
signal both in vitro and in vivo, enhancing chondro-
genic markers and formation of new cartilage [10,11].   
 
Here we examined, for the first time, the effectiveness 
of antagomiR-221 treatment in reverting the degene-
rated/de-differentiated phenotype of cells from enzy-
matically-dispersed low passage-expanded human IVD 
cells. At the same time, this knockdown approach 
allowed us to investigate potential targets of miR-221 in 
a context of tissue degeneration and inflammation not 
investigated before, providing basic information needed 
for the development of effective therapies mainly based 




Cells from IVD: culturing and characterization 
 
The experimental procedure to obtain IVD cells has 
been described in the Material and Methods section and 
in Table 1 the characteristics of the IDD patients have 
been reported. All tissue samples were assessed by 
histology (hematoxylin and eosin) and histochemistry 
(Safranin-O) revealing the presence of matrix proteo-
glycans in hypocellular areas, as shown in the 
representative microphotograph of Figure 1. Passage 
zero (P0) cells showed a morphology very similar to 
that found in the histological preparation and, as 
expected, changed in expanded P2 cells, where the 
predominant form became the flattened one (Figure 1).  
 
After subculture, already at passage 2 (P2), the cells 
have undergone a de-differentiation process by loosing 
the chondrocyte-like phenotype. This was assessed by 
immunocytochemical analysis which revealed a sharp 
decrease in the expression of typical chondrogenic 
markers, including collagen type II alpha 1 chain 
(COL2A1), SRY-box 9 (SOX9) and aggrecan (ACAN) 
(Figure 1). Immunophenotypic profile of P2 cells from 
each culture was determined by flow cytometry show-
ing that the cells were negative for CD14 haemato-
poietic cell marker, and positive for CD105 (80% ± 8%) 
and CD44 (89% ± 5%) mesenchymal cell markers 
(Figure 1). We chose to use P2 cells since they 
represent a good compromise as de-differentiated but no 
senescent cells, suitable for the subsequent efficient 
transfection.  
 
miR-221 expression in IVD cells 
 
Repeated analyses on IVD cells demonstrated that the 
expression of miR-221, previously defined as negative 
regulator of chondrogenesis [10] and mediator of 
inflammatory pathway [12], increased with the degree 
of degeneration. Interestingly, we found that the 
expression levels of miR-221 were always significantly 
higher in IVD cells than in normal human freshly 
isolated chondrocytes [10] used as control, and in P0 
cells from severe IDD than P0 cells from mild IDD 
(Figure 2A). Consistently, the expression levels of miR-
221 significantly increased during the de-differentiation 
process; P2 or P4 cells showed higher levels of miR-
221 than P0 cells (Figure 2B).  
 
These data suggest that degeneration and de-
differentiation are two processes that, for certain 
aspects, can be overlapped acting through potential 
common regulators such as miR-221.   
 
miR-221 silencing in IVD cells 
 
Next, we knocked down miR-221 by siRNA in de-
differentiated P2 cells to determine whether miR-221 
silencing was effective in inducing the expression of 
chondrogenic factors in the absence of exogenously 
added growth factors, as we previously observed in 
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human mesenchymal stem cells (hMSCs) [10,11]. As 
shown in Figure 2C, antagomiR-221 treatment was 
highly effective in miR-221 knockdown after only 48 
hours, achieving >99% inhibition of miR-221 
expression with respect to untreated or antagomiR-
scrambled treated cells. After transfection with 
antagomiR-221 or antagomiR-scrambled, cell viability 
was not modified as determined by Calcein‐AM/PI 
assay (Figure 2C). 
 
Forty-eight hours of antagomiR-221 treatment was 
sufficient in modifing the expression of typical 
chondrogenic markers such as COL2A1, SOX9, and 
ACAN (Figure 2D and E). In particular, SOX9 was up-
regulated both at mRNA and protein level. COL2A1 
and ACAN mRNAs remain relatively unaffected, 








































revealed by qRT-PCR and immunocytochemistry 
analysis, respectively. The lack of correspondence 
between mRNA and protein levels for extracellular 
matrix components is not surprising [13,14] and this 
evidence confirms once again that protein analysis is 
preferable to obtain informative data in this context.   
 
Interestingly, antagomiR-221 treatment was also 
effective in increasing the expression of TRPS1 
(transcriptional repressor GATA binding 1), a repressor 
of calcification and a positive modulator of chondrocyte 
proliferation and differentiation, still poorly investigated 
in IDD (Figure 2D and E) [15]. 
 
Collectively, these data suggest that the silencing of 
miR-221 is critical for addressing the IVD cells towards 









































 IVD level Age Sex Symptoms Duration of symptoms prior to surgery Degeneration 
Donor 1 C5-C6 40 female Tetraparesis (myelopathy) 9 months mild 
Donor 2 C5-C6 47 male Radiculopathy:  pain and palsy 1 month mild 
Donor 3 C5-C6 63 female Radiculopathy:  pain and palsy 3 months mild 
Donor 4 C6-C7 48 male Radiculopathy:  pain and palsy 2 months mild 
Donor 5 C5-C6 64 female Radiculopathy:  pain and palsy; neck pain 3 months severe 
Donor 6 C5-C6 49 female Radiculopathy; neck pain 2 months severe 
Donor 7 C4-C5 34 male 
Paraparesis (myelopathy) 
and radiculopathy: pain 
and paresthesia;  
neck pain 
6 months severe 
Donor 8 C6-C7 41 male Radiculopahty:  pain and paresthesia 3 months severe 
Donor 9 C5-C6 48 male Paraparesis (myelopathy) 12 months severe 
Donor 10 C7-D1 34 male Radiculopathy:  pain and palsy 2 months mild 
Donor 11 C4-C5 68 male Tetraparesis (myelopathy) 12 months severe 
Donor 12 C5-C6 40 female Radiculopathy: pain 2 months mild 
Donor 13 C6-C7 55 male Radiculopathy:  pain and palsy 6 months severe 
Donor 14 C4-C5 70 male Tetraparesis (myelopathy) 3 months severe 
Donor 15 C4-C5 58 male Radiculopathy:  pain and palsy 6 months severe 
Donor 16 C5-C6 44 male Radiculopathy:  pain and palsy 6 months mild 














































miR-221 silencing correlates with FOXO3 up-
regulation 
 
In our effort to elucidate the molecular mechanisms 
supporting miR-221 action in IVD cells, we focused on 
the effect of antagomiR-221 treatment on FOXO3, a 
member of forkhead ‘O’ class transcription factors that 
have been recently defined as critical mediators of IVD 
integrity and function [16, 17]. Computational analysis 
performed with three miRNA databases (miRanda, 














































sequence of FOXO3 identified possible binding sites for 
miR-221. It has already been shown, in a different 
cellular context, that miR-221 targets FOXO3 [18]. We 
found that in most cases analyzed de-differentiated P2 
cells were completely FOXO3 negative. However, the 
expression of FOXO3 analyzed both at mRNA and 
protein level significantly increased in antagomiR-221 
treated P2 cells (Figure 3A). The immunocytochemistry 
showed that the antagomiR-221 treated cells expressed 
functional FOXO3 transcription factor as it was found 
immunolocalized mostly in the nucleus.  
Figure 1.  IVD cells: culturing and characterization. Representative optical photomicrographs showing morphology of  the cells 
(indicated by the arrows) in the IVD tissue stained with Safranin‐O, and at P0 and P2 passages in culture. P2 cells were characterized by 
flow  cytometry  for  the  expression  of  CD14  haematopoietic marker,  and  CD105  and  CD44 mesenchymal markers.  Flow  cytometric 
analysis of a representative case is reported; open histograms represent the isotype control antibody, gray histograms represent anti‐
CD14, ‐CD105 and ‐CD44 antibodies. X‐axis, fluorescent channel; Y‐axis, number of events. Representative optical photomicrographs of 
COL2A1, SOX9 and ACAN  immunostaining performed  in P0 and P2  cells are  reported. Protein expression  levels were quantified by 
densitometric analysis of immunocytochemical pictures using ImageJ software and expressed as means of pixels per one hundred cells 
±SD (P0 group, n = 6; P2 group, n = 6). Exact P‐values are reported. Scale bars: 20 μm. 

















































































































Figure  2.  Evaluation  of  the  effect  of  antagomiR‐221  treatment  on  intervertebral  disc  cells  (IVD)  cells. (A)  Before 
transfection the expression levels of miR‐221 were measured in P0 cells from MILD and SEVERE IDD by qRT‐PCR. Data are presented as 
fold changes relative to control represented by human freshly isolated chondrocytes (hCH). Results represent mean ± SD (hCH group, n = 
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The effect of miR-221 in regulating FOXO3, was further 
investigated by reporter gene assays (Figure 3B). 3’-UTR 
DNA fragment containing the validated miRNA target 




















































into the 3’-UTR of a luciferase reporter gene. Forty-
eight hours after cotransfection of P2 cells with reporter 
gene and miR-221 mimic, a significant down-regulation 






















































expression  levels  of  FOXO3  were  assessed  in  antagomiR‐221  treated  de‐differentiated  P2  cells  by  qRT‐PCR,  Western  blot  and 
immunocytochemistry. mRNA data are presented as fold change relative to untreated cells. Results represent mean ± SD (n = 10). Exact 
P‐values are  reported. Representative Western blot of  FOXO3 protein  is  reported. Bar graphs  show  the densitometric analysis of all 
samples analyzed; β‐Actin was used as  loading control, data were expressed as ratio of FOXO3  in respect to β−Actin and presented as 
mean ±  SD  (n  =  5).  Representative  optical  photomicrographs  of  FOXO3  protein  expression  and  localization  assessed  by 
immunocytochemistry  are  reported.  Protein  levels were  quantified  by  densitometric  analysis  of  immunocytochemical  pictures  using 
ImageJ software and expressed as means of pixels per one hundred cells ±SD (n = 10). Exact P‐values are reported. Scale bars: 20 μm. In 
the  graphs:  antagomiR‐221  (black  column),  scrambled  oligonucleotide  (antagomiR‐scr)  (gray  column)  treated  or  untreated  (white 
column) cells.  (B) Validation of miR‐221 target site in the FOXO3 3’‐UTR by reporter gene assay in IVD cells.  A luciferase reporter vector 
containing partial sequence  (+1602/+2018) of  the FOXO3  3’‐UTR harboring  the predicted miR‐221  target site  (gray  triangle),  in  the 3’ 
UTR of a Nano Luc luciferase gene was used. P2 cells were transfected for 48 hours with a combination of reporter constructs (100 ng) 
along with miR‐221 mimic or Negative  control  (30 nM). Afterwards, Nano  Luc  luciferase  reporter gene  (NlucP) and  Firefly  luciferase 
control reporter activities (luc2) were measured using a Nano‐Glo Dual‐Luciferase assay and represented as mean ±SD (n = 5). Exact P‐















































In order to investigate whether the increase of FOXO3 
affected transcriptional programming, the expression of 
two target genes, manganese-containing superoxide 
dismutase (SOD2) [19] and runt-related transcription 
factor (RUNX2) [20], were evaluated. Previous studies 
indicated that FOXO3 is implicated in the detoxification 
of reactive oxygen species (ROS) through induction of 
SOD2, an enzyme with an important role in cellular 
stress responses [19]. Consistently, a remarkable increase 
of SOD2 expression was found following antagomiR-221 
treatment (Figure 3C), showing that the increase of 
FOXO3 mediated by miR-221 silencing is accompanied 











































SOD2. In addition, we found that antagomiR-221 
treatment maintained low basal expression levels of 
RUNX2 (Figure 3C). RUNX2, the master regulator of 
osteogenesis [20], was recently implicated in the 
progression of IVD aging, degeneration and calcification 
[21]. The range of RUNX2 action is wide and the 
regulation of its expression depends on many different 
factors, including FOXO3 and TRPS1, whose activity is 
strictly controlled by the cellular context. Therefore, the 
increase of SOD2, but not RUNX2, expression suggests 
the achievement of a downstream signaling that 
contributes to revert the de-differentiated phenotype of 
P2 cells after antagomiR-221 treatment.  
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FOXO3 and TRPS1 expression in IVD specimens 
 
The critical role of FOXO3 in IDD was confirmed by 
immunostaining performed on all IVD tissue samples 
and P0 cells derived from them. The results showed that 
the lowest expression levels of FOXO3 were in severe 
degenerated discs (Figure 4A), as well as in the 
corresponding P0 cells compared to P0 cells from mild 
IDD (Figure 4B). Conversely, TRPS1 was expressed at 
comparable levels regardless of the degree of IDD, both 
in IVD tissue and in P0 cells (Figure 4A and B). This 
evidence supports the idea that P0 cells can be 
considered an adequate experimental model mimicking 
the IDD since resemble the characteristics of IVD from 
which derived. Moreover, restoring high levels of 





Understanding molecular mechanisms involved in IDD 
is essential for developing treatments to prevent the 
onset and progression of IDD, in particular those 
treatments based on injectable bioactive molecules 
within the injured disc. 
 
We found that miR-221 is up-regulated in cells from 
degenerated IVD and the aim of this study was to 
investigate the effect of antagomiR-221 treatment in 
reverting the degenerated phenotype of these cells. 
 
In addition to classic gene therapies and cell-based 
tissue engineering approaches [5,22-25], in recent years 
several treatments have been proposed in preclinical 
setting predominantly consisting of direct injection of 
biological agents, ranging from recombinant growth 
factors and matrix proteins [26-30], to Platelet-rich 
plasma (PRP) [31], to nucleic acid based drugs 
including a variety of long and small non-coding RNAs 
(ncRNAs) [5, 32]. Among housekeeping and regulatory 
ncRNAs, miRNAs are important small ncRNAs 
regulators of gene expression, and act by targeting 
mRNAs for translational repression and/or cleavage 
[33]. Increasing evidence shows that strategies to down-
regulate a specific miRNA, or to prevent its up-
regulation, have potential as therapeutic and/or 
preventive approaches in management of a variety of 
human diseases including IDD. However, conflicting 
data or unconvincing results are present in literature, 
mainly due to the difficulty of setting up appropriate in 
vitro or in vivo experimental models. A significant 
differential expression of some miRNAs between 
normal and degenerative NP tissues, and an association 
with the development and progression of IDD have 
been demonstrated, and many knockdown or over-
expression experiments have been performed in vitro. 
For example, it has been demonstrated that MIR133a 
induces the downregulation of COL2A1 by targeting 
matrix metallopeptidase 9 (MMP9), causing the onset of 
IDD [34]; MIR146a suppresses IL-1β-induced MMP13, 
ADAM metallopeptidase with thrombospondin type 1 
motif 4 (ADAMTS4), and ADAMTS5 expression in NP 
cells [35]; MIR98 or MIR27b downregulation 
contributes to the loss of COL2A1 in IDD [36,37]; 
MIR15a and MIR143 promote the progression of NP 
apoptosis by directly targeting BCL2 apoptosis 
regulator [38,39]; MIR15b silencing protects NP cells 
from IL-1β-induced ECM degradation by targeting 
SMAD3 [40]; MIR132 promotes ECM degradation [41] 
in human NP cells by direct targeting of growth 
differentiation factor 5 (GDF5, a member of TGFβ 
superfamily) which is also a target gene of MIR7 [37]; 
MIR210 promotes Fas-mediated apoptosis in human 
IDD by regulating the expression of homeobox A9 
(HOXA9) [42]; MIR494 promotes ECM degradation 
and apoptosis of degenerative human NP cells by 
directly targeting SOX9 [43]; MIR10b is overexpressed 
in IDD and increased NP cell proliferation by targeting 
HOXD10 to derepress the RhoC-Akt signaling [44]; 
concerning miR-221, a recent paper investigated its role 
in the osteogenic differentiation of degenerated annulus 
fibrosus cells [45]. 
 
However, in this context it is important to consider at 
least the two issues described below. In vitro condition 
does not truly represent clinical scenarios since cell 
culture tends to cause the loss of the original cellular 
properties or select a particular cell type, therefore cell 
expansion required for large analysis does not often 
agree with defining the authentic tissue context respon-
se to a specific treatment. Therefore, the accumulation 
of certain characteristics and loss of others, that occur 
with increasing passage numbers, limit the clinical 
correlation. In vitro studies on isolated cellular sub-
populations are useful for cell characterization, but 
poorly represent the ideal approach for understanding 
the response within an heterogeneous physiopatho-
logical microenvironment. Therefore, the results of 
many studies regarding the effectiveness of biological 
therapeutics as injectable anabolic factors able to slow 
or even reverse the degenerative trend of IDD need to 
be interpreted cautiously and carefully. 
 
With this in mind, we tried to perform knockdown 
experiments on short - term culture of IVD primary 
cells. We established a relatively quick protocol, as 
described in the Material and Methods section, which 
allowed i. to produce P0 cells really resembling IVD 
microenvironment, ii. to minimize artifacts from ex-
tended in vitro culture, and iii. to obtain viable cells, by 
a mild enzymatic digestion to avoid completely 
disruption of ECM. We demonstrated that the silencing 
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of miR-221 is able to drive the cells toward chondro-
genic lineage increasing the expression levels of typical 
marker genes such as COL2A1, ACAN and SOX9.  
 
Notably, antagomiR-221 treated cells restored higher 
levels of FOXO3 and TRPS1 attenuating the grade of 
severity based on a molecular point of view. The 
appearance of FOXO3 (a miR-221 validated target in 
other contexts) after antagomiR-221 treatment together 
with demonstration that miR-221 directly targets FOXO3 
also in IVD cells is an important evidence, since the 
expression of this crucial transcription factor significantly 
decreased in human degenerated discs [16, 17].  
 
Specific actions of FOXO proteins, in particular 
FOXO3, have been described in different contexts, 
including the protection against oxidative stress, the 
increase of expression of genes encoding proteins 
involved in DNA repair, the regulation of adult stem 
cell homeostasis, the inhibition of inflammatory 
cytokines production, and the extension of longevity 
[46]. For these reasons, interventions that increase 
FOXO3 level or activity is attracting considerable 
interest, and our evidence suggests that disc homeo-
stasis may be preserved thanks to reactivation of 
FOXO3 by targeting miR-221. 
 
Regarding TRPS1, which is involved in chondrogenesis 
and cartilage biology [15], we hypothesized that 
increase in its expression after miR-221 depletion may 
contribute to avoid undesired ossification in IVD 
microenvironment slowing down the degeneration 
process. In fact, calcification of cartilage cells is one of 
many events associated with IDD multifactorial disease, 
together with apoptosis, senescence, inflammation, and 
alterations in the ECM [2,47]. Therefore, since TRPS1 
acts as a repressor of the function of RUNX2 [15,48], 
the master regulator of osteogenesis [20], the increased 
TRPS1 expression may contribute to maintain RUNX2 
basal level and repress the RUNX2-mediated trans-
activation of genes associated with cartilage hyper-
trophy and ECM degradation, such as collagen type X 
alpha 1 chain (COL10A1), alkaline phosphatase (ALP), 
and MMPs [49], also in the IVD tissue. 
 
Finally, we should also consider some limitations of this 
study as well as further investigation to better determine 
the role of miR-221 in human IDD. First, we did not 
define in detail the cause/effect relationship between the 
antagomiR-221 treatment and a large series of genes 
whose expression could be modulated.  Here we focus-
ed on typical proteins such as COL2A1, ACAN and 
SOX9, whose loss is associated with intervertebral disc 
degeneration, and promising candidates such as FOXO3 
and TRPS1 as potential positive modulators of IVD 
integrity, in order to demonstrate the successful 
phenotypic change following an effective antagomiR-
221 treatment. However, what specific pathways are 
affected by miR-221 in IVD remain to be investigated 
through a global analysis of mRNA profile by RNA 
sequencing. Second, in order to shed light on certain 
aspects of disk disease and the potential for a biological 
therapy with antagomiR-221, further experiments with a 
larger sample size are needed to achieve a more reliable 
outcome. Moreover, we are planning to use highly 
appealing methods such as ex vivo organ culture 
systems with live disc cells, as recently proposed [50].  
 
In conclusion, the present study demonstrates that a low 
number of cells obtainable from short - term culture of 
IVD primary cells, including mature and progenitor 
cells, allows to perform sufficient informative analysis, 
including silencing experiments and comparisons with 
P0 cell status. For the first time we have demonstrated 
that miR-221 may have a significant role in the etiology 
of IDD, suggesting that its down-regulation may play a 
pivotal role in preserving the disc homeostasis and in 
supporting the endogenous repair process. The scenario 
of biological treatment approaches for degenerated disc 
repair is widely expanding, and the use of specific 
molecules combined with adequate delivery systems 
into a degenerating disc appears promising [51]. Accor-
dingly, the potential use of antagomiR-221 in clinical 
practice is an important challenge, and future experi-
ments on animal models aimed at demonstrating the in 
vivo therapeutic effect, will serve to propose the use of 
this molecule as intradiscal injectable molecule. 
 
MATERIALS AND METHODS 
 
Patients and tissue samples 
 
Surgical herniated human disc tissues were obtained 
from 16 donors (patients’ages were between 34 and 70 
years, mean age 50 years, 11 male and 5 female) by 
using research protocol approved by Ethics Committee 
of the University of Ferrara and S. Anna Hospital 
(protocol approved on November 17th, 2016). During 
surgery through an anterior approach, the cervical disc 
was completely removed; sampling was obtained from 
the central core of the disc, in order to avoid anterior 
and posterior longitudinal ligament, as well as calcified 
portions of the discs. The level of disc degeneration was 
classified into two groups, namely mild and severe. 
Discs with mild degeneration are non homogeneous at 
Magnetic Resonance Imaging (MRI) with a hypointense 
dark gray signal intensity, present a dehydrated nucleus 
pulposus, soft consistency at surgery. Discs with severe 
degeneration present hypointense black signal intensity 
at MRI, a very dehydrated nucleus pulposus with cal-
cifications, and hard consistency at surgery. 
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Isolation of human IVD cells 
 
Cervical intervertebral disc tissues (1-2 cm3) were 
collected, cut into small pieces, and subjected to mild 
digestion in 15 ml centrifuge tube with only 1 mg/mL 
type IV collagenase (Sigma Aldrich, St. Louis, USA) 
for 5 h at 37°C in Dulbecco’s Modified Eagle’s 
Medium (DMEM)/F12 (Euroclone S.p.A., Milan, Italy). 
The tube was shaken every 2 min and once the digestion 
was terminated, cell suspension was filtered with a 
Falcon™ 70 μm Nylon Cell strainer (BD Biosciences, 
Franklin Lakes, NJ, USA). Subsequently 300 xg 
centrifugation was conducted for 10 min, the super-
natant discarded, the cells resuspended in basal 
medium (DMEM/F12 containing 15 % fetal calf 
serum, 100 mg/mL streptomycin, 100 U/mL penicillin, 
and 1 % Glutamine) (Euroclone) and seeded in 
polystyrene culture plates (Sarstedt, Nümbrecht, 
Germany) at 5000 cells/cm2. The cells that were 
released from the dissected tissue and maintained in 
culture at 37 °C in a humidified atmosphere with 5 % 
CO2 within the first 48 hours were referred to as 
passage zero (P0) cells. P0 cells were expanded for a 
maximum of two passages by growing for a period not 
exceeding a week until subconfluent, detaching by 
trypsinization, and maintained in culture for two 
passages to obtain P2 cells. Where indicated the cells 
were expanded up to passage 4 (P4). At each passage 
the cells were subjected to cell morphology and gene 
expression analysis. 
 
Freshly isolated chondrocytes from human nasal septum 
cartilage were obtained as previously described [10] and 




IVD progenitors were analyzed for the expression of 
mesenchymal and hematopoietic surface marker 
molecules, by direct immunofluorescent staining, as 
previously reported [10]. Briefly, cell pellets were 
resuspended in phosphate buffered solution (PBS), and 
incubated with fluorescein isothiocyanate (FITC)– or 
phycoerythrin (PE)–conjugated mouse anti-human 
antibodies CD14-FITC (#F0844; DakoCytomation; 
Dako, Glostrup, Denmark), CD44-PE, and CD105-PE 
(#550989, #560839; Becton Dickinson, Franklin Lakes, 
NJ, USA) for 15 min at 4 °C. Monoclonal antibodies 
with no specificity were used as negative control. 
Antibody-treated cells were then washed with PBS and 
spun down (300 xg). Cell pellets were resuspended in 
400 μL of PBS and analyzed by FACS Scan (Becton 
Dickinson). For each sample, 20000 events were 




P2 cells were seeded in polystyrene culture plates (1.82 
cm2 area) (Sarstedt) until reaching 70 % of confluence. 
After 24 h cells were transiently transfected with 30 nM 
antagomiR-221 (GAAACCCAGCAGACAAUGUAGC 
U) (Ambion Life Technologies, Grand Island, NY), a 
non-relevant antagomiR (antagomiR-Scr) (Ambion Life 
Technologies) in basal medium added with 20 % Opti-
MEM™ (ThermoFisher Scientific, Waltham, USA).  
For all transfections, Lipofectamine RNAiMAX 
(ThermoFisher) was used as delivering agent (0.43 
μL/mL of culture medium) by combination with the 
oligonucleotides for 20 min at room temperature.. The 
transfected cells were cultured for 48 h at 37 °C, in a 
humidified atmo-sphere at 5 % CO2, then detached and 




Viability of the cells was assessed by Calcein-
AM/propidium iodide (PI) staining (Cellstain double 
staining kit, Sigma-Aldrich). Before staining, the 
medium was removed from the wells, and 500 μL of the 
staining solution was added to each well. The samples 
were incubated in the dark at room temperature for 15 
min, thereafter the wells were rinsed with PBS and 
immediately visualized under a fluorescence micro-
scope (Nikon, Optiphot-2; Nikon Corporation, Tokyo, 
Japan).  Dead cells stained red, while viable ones 
appeared green.   
  
Luciferase reporter gene assay 
 
DNA fragment of the FOXO3 (507 bp) 3’-UTR to 
encompass miR-221 predicted target site, was inserted 
into the XhoI-XbaI restriction sites in the multiple 
cloning site of the reporter vector pmiRNano-GLO 
(Promega). This bicistronic vector contains NanoLuc 
luciferase (NlucP) as the primary reporter gene and 
Firefly luciferase (Luc2) as control reporter for 
normalization. Primers used in the PCR were, Forward 
FOXO3 3’-UTR:  CCGCTCGAGTCCCTGCTTGAGTT 
CTTGCTGAT, which contains the XhoI restriction site 
(CTCGAG), Reverse FOXO3 3’-UTR GCTCTAGATT 
CACTGCTACTGGAAAGT, which contains the XbaI 
restriction site (TCTAGA). IVD cells were transfected 
with 100 ng of reporter vector in combination with 30 
nM of pre-miR-221 precursor (named miR-221 mimic), 
or Negative control (all purchased from Ambion Life 
Technologies), using Lipofectamine 2000 reagent 
(ThermoFisher). After 48 hours, transfected IVD cells 
underwent NanoLuc and Firefly luciferase activity 
measurements using the GloMax 20/20 single tube 
Luminometer (Promega) and the Nano-Glo Dual-
Luciferase Assay (Promega) according to the manufac-
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turer’s recommendations. The ratio NanoLuc reporter 
activity/Firefly control reporter activity was calculated 
for each well. For each IVD sample all transfections 
were performed in triplicate, and data were presented as 




Immunocytochemistry analysis was performed 
employing the ImmPRESS (#MP-7500; Vectorlabs, 
Burlingame, CA).  Cells grown in polystyrene culture 
plates were fixed in cold 100% methanol and 
permeabilized with 0.2 % (v/v) Triton X-100 (Sigma-
Aldrich) in TBS (Tris-buffered saline). Cells were 
treated with 3 % H2O2 in TBS, and incubated in 2 % 
normal horse serum (Vectorlabs) for 15 min at room 
temperature. After the incubation in blocking serum, 
the different primary antibodies were added and 
incubated at 4 °C overnight: polyclonal antibodies for 
COL2A1 (#Ab3092; mouse anti-human, 1:200 
dilution, Abcam, Cambridge, UK), SOX9 (#sc-20095; 
rabbit anti-human, Santa Cruz Biotechnology), ACAN 
(#sc-33695; mouse anti-human, 1:200 dilution, Santa 
Cruz Biotechnology), TRPS1 (#20003-1-AP; rabbit 
anti-human, 1:100 dilution; Abcam), FOXO3 
(#Ab70315; rabbit anti-human, 1:1000 dilution; 
Abcam), RUNX-2 (#sc-10758; rabbit anti-human, 1:100 
dilution; Santa Cruz Biotechnology) and SOD2 (#sc-
133134; mouse anti-human; 1:200 dilution; Santa Cruz 
Biotechnology). Cells were then incubated in Vecstain 
ABC (#MP-7500; Vectorlabs) with DAB solution 
(#SK-4105; Vectorlabs). After washing, cells were 
mounted in glycerol/TBS 9:1 and observed using a 
Leitz microscope (Wetzlar, Germany). Quantitative 
image analysis of immunostained cells was obtained by 
a computerized video-camera – based image-analysis 
system (with NIH, USA ImageJ software, public 
domain available at: http://rsb.info.nih.gov/nih-image/) 
under brightfield microscopy. Briefly, images were 
grabbed with single stain, without carrying out nuclear 
counterstaining with hematoxylin and unaltered TIFF 
images were digitized and converted to black and 
white picture to evaluate the distribution of relative 
gray values (i.e. number of pixels in the image as a 
function of gray value 0-256), which reflected 
chromogen stain intensity. Images were then segment-
ed using a consistent arbitrary threshold 50% to avoid 
a floor or ceiling effect, and binarized (black versus 
white); total black pixels per field were counted and 
average values were calculated for each sample. Three 
replicate samples and at least ten fields per replicate 
were subjected to densitometric analysis. We performed 
the quantification of pixels per 100 cells and not per 
area in order to take into account the different cell 
morphology and confluence. 
RNA extraction and quantitative real-time (qRT)-
PCR 
 
Total RNA, including miRNAs, was extracted from 
IVD cells using the RNeasy Micro Kit (Qiagen, Hilden, 
Germany), according to the manufacturer’s instructions. 
RNA concentration and quality was measured using a 
NanoDrop ND1000 UV-VIS spectro-photometer 
(Isogen Life Science, de Meern, the Netherlands). 
cDNA was synthesized from total RNA in a 20 μL 
reaction volume using the TaqMan MicroRNA Reverse 
Transcription kit (ThermoFisher) for analysis of 
microRNAs, or the TaqMan High Capacity cDNA 
Reverse Transcription kit (ThermoFisher) for analysis 
of mRNAs. Quantification of miR-221 was performed 
using the TaqMan MicroRNA Assays (ThermoFisher), 
using U6 snRNA for normalization. For the quan-
tification of COL2A1, ACAN, SOX9, FOXO3 and 
TRPS1 mRNA, the appropriate TaqMan Assays were 
purchased (ThermoFisher); Glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) gene was used for 
normalization of mRNA abundance. Polymerase chain 
reactions were performed with the TaqMan Universal 
PCR MasterMix (ThermoFisher) using the CFX96TM 
PCR detection system (Bio-Rad, Hercules, CA, USA). 
Relative gene expression was calculated using the 
comparative 2-ΔΔCt method (expressed as fold change). 
All reactions were performed in triplicate and the 
experiments were repeated at least six times.    
 
Western blot analysis 
 
Total cell extracts were prepared from IVD cells as 
previously reported [10]. 20 μg of each sample were 
electrophoresed through a 4-15% SDS-polyacrylamide 
gradient gel. The proteins were then transferred onto an 
Immobilon-P PVDF membrane (Millipore, Billerica, 
MA). After blocking with TBS-0.1 % Tween-20 and 5% 
nonfat dried milk (Sigma-Aldrich), the membrane was 
probed with monoclonal mouse anti-human FOXO3 
antibody (#sc-48348, clone D-12; 1:1000 dilution) (Santa 
Cruz Biotechnology).  After washing with TBS-0.1% 
Tween 20, the membranes were incubated with the 
appropriate horseradish peroxidase conjugated secondary 
antibody (Dako, Glostrup, Denmark). Immunocomplexes 
were detected using Immobilon Western Chemi-
luminescent HRP Substrate (Merck-Millipore). A mouse 
monoclonal anti-β-actin antibody (Sigma-Aldrich) was 
used for normalization. Densitometric analysis was 
performed by ImageJ software (NIH, USA, public 




Small fragments of each IVD sample were rinsed with 
PBS, fixed in 4 % buffered paraformaldehyde for 24 h 
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at 4 °C, embedded in paraffin and cross-sectioned (5-
μm thick). For histological evaluation non consecutive 
sections were stained with 0.1% Safranin-O solution or 
immunostained with TRPS1 (#20003-1-AP; rabbit anti-
human, 1:100 dilution; Abcam) and FOXO3 
(#Ab70315; rabbit anti-human, 1:100 dilution; Abcam). 
Immunohistochemical sections were deparaffinized, 
rehydrated, and enzymatically treated with 20 μg/mL of 
proteinase K. Slides were then processed with 0.3 % 
H2O2 in PBS 1X for 5 min and with blocking solution 
(PBS/1 % BSA/10 % FCS)for 30 min at room 
temperature. Then the slides were incubated over night 
with the primary antibody at 4 °C, followed by 
treatment with Vecstain ABC reagent (Vectorlabs) for 
30 min. The reactions were developed using DAB 
solution (Vectorlabs), the sections were counterstained 
with hematoxylin and mounted in glycerol. The stain-
ings were quantified by a computerised video camera-
based image analysis system (NIH, USA ImageJ 
software, public domain available at: http://rsb.info. 
nih.gov/nih-image/) under brightfield microscopy 
(NikonEclipse 50i; Nikon Corporation, Tokyo, Japan), 
as reported above. For the analysis of sections, positive 
cells in the area were counted and protein levels 
expressed as % of positive nuclei (ten fields per 




Data are reported as mean value ± standard deviation 
(SD). Comparison between two groups were assessed 
by unpaired Student’s t test. All statistical analyses were 
performed using Prim 6 software (GraphPad Software). 
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